Apixaban in heparin-induced thrombocytopenia

Phase 2

Recruiting

• Conditions: Heparin-induced thrombocytopenia.; Thrombocytopenia, unspecified; D69.6

• Registration Number: IRCT20200325046854N1
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 May 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1) Age 18 years or older
2) HIT detection based on 4T Score equal to or above 4

Exclusion Criteria

Patients with active bleeding
Patient with inherited or acquired coagulation disease or bleeding disorder
Patients receiving cytochrome P-450 3A4 inhibitors or inducers
Severe renal failure (CrCl <25 ml / min)
Severe liver disease (including Child-Pugh B and C)
The patient needs surgery
History of uncorrected cerebral aneurysm, intracranial tumor or vascular accident
Non-participation in research projects during the 30 days prior to the study
Pregnant and lactating women
Previous treatment with a non-heparin anticoagulant
Covid-19 infection

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Follow-up of arterial / venous thrombosis after receiving apixaban. Timepoint: If the patient becomes symptomatic. Method of measurement: Doppler ultrasound.

Secondary Outcome Measures

Name	Time	Method
Mortality rate. Timepoint: Daily. Method of measurement: Loss of vital signs and death of the patient.;Bleeding event following the use of apixaban. Timepoint: Daily. Method of measurement: Based on the patient's symptoms such as petechiae.